Univ Lille, Faculté de Médecine, CHU Lille, Laboratoire de Virologie EA3610, Lille, France.
CHU de Lille, Service des Maladies de l'Appareil Digestif, Lille, France.
J Med Virol. 2018 May;90(5):989-993. doi: 10.1002/jmv.25028. Epub 2018 Jan 30.
We investigated the decline of hepatitis B virus surface antigen (HBsAg) and core related antigen (HBcrAg) in chronic hepatitis B patients sussessfully treated with nucleos(t)ide analogues. In patients with plasma viral suppression, the baseline median levels of HBsAg and HBcrAg were 3.1 and 3.0 log U/mL, respectively. The levels in naïve patients were 4.2 and 3.6 log U/mL for HBsAg and HBcrAg, respectively. No significant decline was observed in patients with viral suppression within a year period. A low reduction was observed during the first months after treatment initiation, especially regarding HBcrAg. The dynamics of these antigens after viral suppression should be further investigated.
我们研究了成功接受核苷（酸）类似物治疗的慢性乙型肝炎患者乙型肝炎病毒表面抗原（HBsAg）和核心相关抗原（HBcrAg）的下降情况。在病毒血症得到抑制的患者中，HBsAg 和 HBcrAg 的基线中位数水平分别为 3.1 和 3.0 log U/mL。初治患者的 HBsAg 和 HBcrAg 水平分别为 4.2 和 3.6 log U/mL。在病毒抑制的 1 年内，未观察到患者的水平有显著下降。在治疗开始后的头几个月观察到低幅度下降，尤其是 HBcrAg。HBsAg 和 HBcrAg 在病毒抑制后的动力学变化仍需进一步研究。
